Pharmaceutical giant Novo Nordisk announced that it cooperates with weight watchers to offer Wegovy via Novocare Pharmacy, with effect from 1 July.
Via the partnership, the TeleHealth program of Weightwatchers, integrated in Novocare Pharmacy, will enable new uninsured or self-paying patients to gain access to Wegovy for $ 299 per month for a month for each dose and then $ 499 a month thereafter. The offer is valid from July 1 to July 31.
Novo Nordisk says that the offers patients will help “previously prescribed untrained ‘semaglutide’ start on Wegovy approved by the FDA.”
Weightwatchers will hand over Wegovy via Centerwell Pharmacy, which handles the version and delivery of prescription for Novocare Pharmacy.
Novo Nordisk said that the offer will be effective by each of his TeleHealth partners: Ro, lifemded and now weight watchers. The same deal will also be available for patients directly via Novocare Pharmacy.
“We understand that how people choose to receive care changes, and in response we work together with weight watchers to provide more accessible care to those who live with chronic obesity,” said Dave Moore, executive vice president of the American operations of Novo Nordisk, in a statement.
“Weightwatchers have spent more than six decades on building a science-supported weight management approach, and we see a strong synergy in our shared dedication to improve health results in the long term. We are also very encouraged with our existing Ro- and Lifemds collaborations.
The larger trend
Earlier this week, Novo Nordisk announced that it ended his contract with HIMS & HARE, that it was announced less than two months ago, claiming that the direct-to-consumer Virtual Care Company breaks the federal law by selling composite versions of the medicine on a scale under the prospect of “personalization”.
Novo Nordisk accused him and her of the use of misleading marketing practices, which claims that patient safety endangers.
HIMS and HARE responded to the allegations and wrote LinkedIn“This is a step of a pharmaceutical giant to protect his own interests by challenging legal, personalized composite care. The effort is even more disturbing to combine legal compounders with bad actors. That is misleading and harmful, especially for patients with complex needs.”
The CEO of the company, Andrew Dedum, wrote on X“In recent weeks, the commercial team of Novo Nordisk has increasingly put us under pressure to control clinical standards and to control patients to Wegovy, regardless of whether it was clinically best for patients. We refuse to be strongly armed by the anti -competitive demands of a pharmaceutical company that infringes the independent decision of the Supplier and the Patient decision.”
Novo Nordisk also works together with direct-to-consumer Virtual Care Company RO and publicly traded telemedicine company lifemded to sell its weight loss medicine through the TeleHealth providers to cash paying customers.
In a statement in which the partnership Weightwatchers was announced, the pharmaceutical giant said: “Ro and lifemdemendaries continue on the basis of their dedication to offer safe and effective medical treatment for patients living with chronic diseases; dialogue with other to the current companies.”
#Novo #Nordisk #cooperates #weightwatchers #Hims #Hare #Fallout